GlassScriptPhysician profile
Jared Wilson
NPI 1922532977
$25,835.31
in general payments reported to CMS, 2019-2025
30 companies · $15K in 2025
The $15K reported for 2025 was more than what 98% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.92 · 2022: $2,913 · 2023: $2,491 · 2024: $5,322 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $7,947 · Travel and Lodging: $2,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,500.00 |
| Food and Beverage | $7,946.88 |
| Travel and Lodging | $2,445.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Izi Medical Products, LLC | $12,500.00 | 2025 | |
| Medtronic, INC. | $7,084.37 | 2021-2025 | Intellis Adaptivestim, Vanta Adaptivestim, Synchromedii |
| Nevro Corp. | $1,791.41 | 2022-2024 | Senza |
| Abbott Laboratories | $1,094.89 | 2022-2025 | Eterna, Proclaim |
| Nalu Medical, INC. | $531.16 | 2023-2024 | Nalu Neurostimulation System |
| Boston Scientific Corporation | $471.88 | 2022-2025 | Intracept, Wavewriter Alpha Prime 16 |
| Abbvie INC. | $467.91 | 2022-2025 | Botox, Qulipta, Ubrelvy |
| Collegium Pharmaceutical, INC. | $411.69 | 2022-2025 | Xtampza, Belbuca |
| Curonix LLC | $202.91 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Spr Therapeutics, INC | $178.86 | 2023 | Sprint Pns System |
| Saluda Medical Americas, INC. | $112.70 | 2025 | Evoke |
| Biotronik Nro, INC. | $110.74 | 2024 | Prospera |
| Vertex Pharmaceuticals Incorporated | $95.80 | 2025 | |
| Tersera Therapeutics LLC | $91.85 | 2023-2025 | Prialt |
| Lundbeck LLC | $77.83 | 2024-2025 | Vyepti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $77.81 | 2023 | |
| Amgen INC. | $61.75 | 2023 | Evenity, Prolia |
| Merz Pharmaceuticals, LLC | $60.56 | 2024-2025 | Xeomin |
| Globus Medical, INC. | $59.04 | 2025 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $52.31 | 2022 | |
| Amneal Pharmaceuticals LLC | $41.10 | 2023 | Lioresal (Baclofen) |
| Microtransponder, INC. | $38.20 | 2024 | |
| Electronic Waveform Lab, INC. | $36.70 | 2025 | |
| Averitas Pharma INC. | $32.19 | 2023 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.03 | 2022-2024 | Relistor |
| Si-Bone, INC. | $30.26 | 2022 | |
| Scilex Pharmaceuticals INC. | $29.24 | 2023-2024 | Ztlido |
| Protega Pharmaceutials INC | $25.70 | 2025 | Roxybond |
| Valinor Pharma, LLC | $19.07 | 2025 | Movantik |
| International Rehabilitative Sciences, INC | $15.35 | 2024 | Rs 4i Plus Sequential Stimulator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.